BEMPEG (monotherapy and in combination with NIVO) increases proliferation and infiltration of CD8+ cytotoxic T cells and natural killer cells with limited expansion of unwanted regulatory T cells in the tumor microenvironment [2–4]. The gene discussed is CD8A; the disease is neoplasm.